유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrelhydrogensulfat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotiske midler - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. forebyggelse af atherothrombotic og tromboemboliske hændelser i atrial fibrillationin voksne patienter med atrieflimren, der har mindst en risikofaktor for vaskulære hændelser, er ikke egnede til behandling med vitamin-k-antagonister, og som har en lav risiko for blødning, clopidogrel er indiceret i kombination med asa til forebyggelse af atherothrombotic og tromboemboliske hændelser, herunder slagtilfælde.

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

stravencon ltd. - cefuroximnatrium - pulver til injektions-/infusionsvæske, opløsning - 1500 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

stravencon ltd. - cefuroximnatrium - pulver til injektionsvæske, opløsning - 250 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

padma europe gmbh - aegle marmelos frugt, pulver, gul potentil, islandsk mos, kaempferia galanga rhizoma, kryddernellike, morgenfrue blomst, myrobalan frugt, paternostertræ, frugt - tabletter

덴마크 - 덴마크어 - SEGES Landbrug & Fødevarer

cheminova a/s - dimethoat, gamma-cyhalothrin - flydende middel - 400 g/l dimethoat; 4 g/l gamma-cyhalothrin

덴마크 - 덴마크어 - SEGES Landbrug & Fødevarer

cheminova a/s - dimethoat, gamma-cyhalothrin - flydende middel - 400 g/l dimethoat; 6,4 g/l gamma-cyhalothrin

덴마크 - 덴마크어 - SEGES Landbrug & Fødevarer

de sangosse ltd. - sprede-klæbemiddel - flydende middel - 1000 g/l sprede-klæbemiddel

덴마크 - 덴마크어 - SEGES Landbrug & Fødevarer

globachem nv - metconazol - emulsionskoncentrat - 90 g/l metconazol

유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - immune sera og immunoglobuliner, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.